Umfang:
Online-Ressource (digital)
ISBN:
9780387894454
,
9780387894447
Serie:
SpringerLink
Inhalt:
An estimated 1.5 million patients in the United States are diagnosed with cancer every year and over half-a-million individuals die of the disease. Since the vast majority of the deaths occur after medical intervention with anticancer therapy, both conventional chemotherapy and novel targeted therapy, it can be concluded that these patients die from drug resistant cancers. A growing number of studies have revealed that mechanisms underlying the development of drug resistance in cancer cells are manifold and complex and very likely are dependent on cell and microenvironment context. In view of these facts, it is important to document the mechanisms of drug resistance and understand which are the dominant resistance pathways in a particular tumor type that could provide potential therapeutic targets in a clinical setting. This book serves as a single source for the current knowledge on genetic and epigenetic alterations that contribute to the development of drug resistance. Comprehensive reviews written by renowned experts provide great insight on the current knowledge on drug resistance mechanisms. This book is a ready source of information to clinicians, cell and cancer biologists and defines molecular drug resistance mechanisms that are challenging scientists and clinical oncologists today. The EditorsDr. Kapil Mehta is a Professor in the Department of Experimental Therapeutics, The University of Texas M. D Anderson Cancer Center, Houston, TX. He has published widely and received several patents on novel discoveries relating to drug resistance in the field of cancer therapeutics. Dr. Zahid H. Siddik is also a Professor in the Department of Experimental Therapeutics at The University of Texas M.D. Anderson Cancer Center. He has studied extensively the mechanisms of drug action and resistance, and is recognized for his seminal studies with platinum-based antitumor agents.
Anmerkung:
Includes bibliographical references and index
,
Foreword; Contents; Contributors; 1 Multidrug Resistance Mediated by MDR-ABC Transporters; Introduction; Mechanistic Aspects of ABC Transporters; MDR-ABC Transporters; Transported Substrates; Gene Regulation; Significance of MDR-ABC Transporters in Cancer; Association of MDR-ABC Transporters with Treatment Failure; Overcoming MDR with Inhibitors; Emerging Role of MDR-ABC Transporters in Resistance Against Targeted Agents; Conclusion; References; 2 Metastasis and Drug Resistance; Introduction; The Pathogenesis of Metastasis; Multidrug Resistance; Reversal of Experimental MDR
,
Calcium Channel BlockersVerapamil and Other Clinically Approved Agents; Verapamil Derivatives and Other Experimental Calcium Channel Blockers; Calmodulin Antagonists; Antibiotics and Analogs; Indole Alkaloids; Cyclosporins and Analogs; Hormones and Antihormones; Pharmaceutical Emulsifying Surfactants; Liposomal Encapsulation; Other Molecules; Clinical Reversal of MDR; Overview of Experimental MDR-Reversal; Metastasis and Drug Resistance; Tumor Angiogenesis; Antivascular Therapy of MDR Prostate Carcinoma; References; 3 The Role of Autophagy and Apoptosis in the Drug Resistance of Cancer
,
IntroductionRole of Autophagy in the Drug Resistance of Cancer; Role of Autophagy in Cancer Treatment; Role of Autophagy in Tumorigenesis; Mechanism Regulating Autophagy and Apoptosis; PI3K-AKT-mTOR Signaling Pathway; BECN1; BCL2 and Adenovirus E1B 19kDa Interaction Protein 3 (BNIP3); p53 Tumor Suppressor Pathway; ER Stress; Other Pathways; Targeting Autophagy in Drug Resistance of Cancer; Crosstalk Between Autophagy and Apoptosis; Combination Treatment for Drug Resistance; Conclusion; References; 4 Mechanisms of Resistance to Targeted Tyrosine Kinase Inhibitors; Introduction
,
Discovery of Viral and Cellular OncogenesBCR-ABL Targeted Therapy; The Philadelphia Chromosome; BCR-ABL Signaling in CML; Imatinib; Imatinib Resistance in CML; Nonmutation-Dependent Mechanisms; Mutation of BCR-ABL; Second-Generation BCR-ABL Inhibitors Aimed at Overcoming Imatinib Resistance; Dasatinib; Dasatinib Resistance; Nilotinib; Overcoming T315I Resistance; EGFR-Targeted Therapy; EGFR and Cancer; Gefitinib and Erlotinib: EGFR-Targeted Therapies; Response to Gefitinib Treatment; Erlotinib; Gefitinib and Erlotinib Resistance; Secondary EGFR Mutations
,
Non-EGFR Mutation-Dependent MechanismsOvercoming T790M Resistance; Concluding Remarks; References; 5 Targeting Transglutaminase-2 to Overcome Chemoresistance in Cancer Cells; Introduction; TG2The Protein with a Split Personality; TG2, Drug Resistance, and Metastasis; TG2-Mediated Cell Signaling; TG2-Mediated NF-B Activation; TG2 Promotes Cell Survival and Chemoresistance; Therapeutic Significance of TG2; Conclusions; References; 6 Extracellular Matrix-Mediated Drug Resistance; Introduction; ECM Proteins Promote Drug Resistance; Mechanisms of ECM-Mediated Drug Resistance
,
Altered Drug Penetration
Weitere Ausg.:
ISBN 9780387894447
Weitere Ausg.:
Buchausg. u.d.T. ISBN 9780387894447
Sprache:
Englisch
DOI:
10.1007/978-0-387-89445-4
URL:
Volltext
(lizenzpflichtig)
Mehr zum Autor:
Mehta, Kapil
Bookmarklink
